Table 1.

Clinical resistance profiles and in vitro susceptibilities of field isolates of L. donovani to Sb(III) and Sb(V)

Straina	Collection area	Clinical drug response	Ldf score	Mean index of resistance ±SD
				Sb(III)	Sb(V)
Lddb	Laboratory	Sensitive		1d	1e
S1c	Ballia (BHU/NMW-5)	Sensitive area	2+	0.667 ± 0.078	0.98 ± 0.06
S2	Muzaffarpur	Resistant area	1+	0.712 ± 0.032	0.93 ± 0.07
S3	Pard 111/3	Sensitive area	2+	0.868 ± 0.015	0.91 ± 0.06
R1c	Muzaffarpur	SAG resistant	NAg	3.18 ± 0.028	2.37 ± 0.13
R2	Muzaffarpur	Resistant area	2+	1.912 ± 0.039	1.77 ± 0.09
R3	Muzaffarpur	SAG resistant	1+	2.34 ± 0.046	1.70 ± 0.06
R4	Muzaffarpur	Amphotericin B resistant	NA	1.87 ± 0.043	2.05 ± 0.07
R5	Ballia (BHU/NMW-17)	Sensitive area	4+	2.20 ± 0.042	1.83 ± 0.10

^aS, sensitive; R, resistant.

^bLdd, L. donovani sensitive laboratory reference strain Dd8.

^cField isolates S1 and R3 are the same as those described by Mittal et al. (36). Their responses to SAG (sensitive/resistant) had been confirmed under in vivo conditions in a hamster model. Sb(III) and Sb(V) resistance indices were calculated using the formula IC_50isolates/IC_50Dd8.

^dIC₅₀, 31.1 ± 0.99 μg/ml.

^eIC₅₀, 91.7 ± 4.1 μg/ml.

^fLd, Leishman-Donovan bodies.

^gNA, not applicable.